Download PDF
Semin Respir Crit Care Med 2008; 29(2): 211-219
DOI: 10.1055/s-2008-1063859
© Thieme Medical Publishers

Update on Echinocandin Antifungals

Carol A. Kauffman1 , Peggy L. Carver2
  • 1Division of Infectious Diseases, Department of Internal Medicine, Veterans Affairs Ann Arbor Healthcare System, University of Michigan Medical School, Ann Arbor, Michigan
  • 2University of Michigan College of Pharmacy, Ann Arbor, Michigan
Further Information

Publication History

Publication Date:
26 March 2008 (online)

    Permissions and Reprints

ABSTRACT

Echinocandins are semisynthetic lipopeptides that competitively inhibit an essential cell wall component of Candida and Aspergillus. They are generally inactive against other fungi. Resistance to these agents is infrequent to date. Echinocandins exhibit low oral bioavailability and are available only as parenteral formulations that are dosed once daily. None of the echinocandins serve as major substrates, inducers, or inhibitors of cytochrome P450 enzymes or the P-glycoprotein transport system; thus they have a low potential for serious drug-drug interactions. In candidemia trials, all echinocandins showed similar rates of success and were as efficacious as fluconazole, amphotericin B, or lipid formulations of amphotericin B.

Caspofungin and micafungin have been studied as single-agent therapy in patients with invasive aspergillosis and will likely remain as second-line agents. However, because of their unique mechanism of action, echinocandins are ideally suited for use in combination with polyenes or azoles and are likely to be used increasingly in immunosuppressed hosts despite a current lack of controlled trials demonstrating efficacy. Limited experience suggests that caspofungin and micafungin are safe to use in pediatric patients. Hospital formulary committees are likely to view the three echinocandins as equivalent agents and place the least expensive agent on formulary.

KEYWORDS

Caspofungin - micafungin - anidulafungin - candidemia

REFERENCES

  • 1 Denning D W. Echinocandin antifungal drugs.  Lancet. 2003;  362 1142-1151
    CrossrefPubMedGoogle Scholar
  • 2 Pfaller M A, Boyken L, Hollis R J et al.. In vitro activities of anidulafungin against more than 2500 clinical isolates of Candida spp. including 315 isolates resistant to fluconazole.  J Clin Microbiol. 2005;  43 5425-5427
    CrossrefPubMedGoogle Scholar
  • 3 Pfaller M A, Boyken L, Hollis R J et al.. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance.  J Clin Microbiol. 2006;  44 760-763
    CrossrefPubMedGoogle Scholar
  • 4 Ghannoum M, D'Angelo M. Anidulafungin: a potent antifungal that targets Candida and Aspergillus .  Infect Dis Clin Pract. 2005;  13 165-178
    CrossrefPubMedGoogle Scholar
  • 5 Pfaller M A, Boyken L, Hollis R J et al.. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.  J Clin Microbiol. 2006;  44 3533-3538
    CrossrefPubMedGoogle Scholar
  • 6 Ostrosky-Zeichner L, Rex J H, Pappas P G et al.. Antifungal susceptibility survey of 2000 Candida bloodstream isolates in the United States.  Antimicrob Agents Chemother. 2003;  47 3149-3154
    CrossrefPubMedGoogle Scholar
  • 7 Pfaller M A, Diekema D J. Epidemiology of invasive candidiasis: a persistent public health problem.  Clin Microbiol Rev. 2007;  20 133-163
    CrossrefPubMedGoogle Scholar
  • 8 Barchiesi F, Sprehhini E, Tomassetti S et al.. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis .  Antimicrob Agents Chemother. 2006;  50 2719-2727
    CrossrefPubMedGoogle Scholar
  • 9 Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.  J Clin Microbiol. 1998;  36 2950-2956
    PubMedGoogle Scholar
  • 10 Tawara S, Ikeda F, Maki K et al.. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.  Antimicrob Agents Chemother. 2000;  44 57-62
    PubMedGoogle Scholar
  • 11 Messer S A, Kirby J T, Sader H S et al.. Initial results from a longitudinal international surveillance programme for anidulafungin.  J Antimicrob Chemother. 2004;  54 1051-1056
    CrossrefPubMedGoogle Scholar
  • 12 Deresinski S C, Stevens D A. Caspofungin.  Clin Infect Dis. 2003;  36 1445-1457
    CrossrefPubMedGoogle Scholar
  • 13 Chandrasekar P H, Sobel J A. Micafungin: a new echinocandin.  Clin Infect Dis. 2006;  42 1171-1178
    CrossrefPubMedGoogle Scholar
  • 14 Vazquez J A, Sobel J D. Anidulafungin: a novel echinocandin.  Clin Infect Dis. 2006;  43 215-222
    CrossrefPubMedGoogle Scholar
  • 15 Odds F C, Motyl M, Andrade R et al.. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.  J Clin Microbiol. 2004;  42 3475-3482
    CrossrefPubMedGoogle Scholar
  • 16 Park S, Kelly R, Kahn J N et al.. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.  Antimicrob Agents Chemother. 2005;  49 3264-3273
    CrossrefPubMedGoogle Scholar
  • 17 Miller C D, Lomaestro B W, Park S et al.. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin.  Pharmacotherapy. 2006;  26 877-880
    CrossrefPubMedGoogle Scholar
  • 18 Laverdiere M, Lalonde R G, Baril J G et al.. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.  J Antimicrob Chemother. 2006;  57 705-708
    CrossrefPubMedGoogle Scholar
  • 19 Hernandez S, Lopez-Ribot J L, Najvar L K, McCarthy D I, Bocanegra R, Graybill J R. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis.  Antimicrob Agents Chemother. 2004;  48 1382-1383
    CrossrefPubMedGoogle Scholar
  • 20 Krogh-Madsen M, Arendrup M C, Heslet L, Knudsen J D. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient.  Clin Infect Dis. 2006;  42 938-944
    CrossrefPubMedGoogle Scholar
  • 21 Dodgson K J, Dodgson A R, Pujol C et al.. Caspofungin resistant C. glabrata .  Clin Microbiol Infect. 2005;  11(Suppl 2) 364
    PubMedGoogle Scholar
  • 22 Moudgal V, Little T, Boikov D et al.. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis.  Antimicrob Agents Chemother. 2005;  49 767-769
    CrossrefPubMedGoogle Scholar
  • 23 Hakki M, Staab J F, Marr K A. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.  Antimicrob Agents Chemother. 2006;  50 2522-2524
    CrossrefPubMedGoogle Scholar
  • 24 Perlin D S. Resistance to echinocandin-class antifungal drugs.  Drug Resist Updat. 2007;  10 121-130
    CrossrefPubMedGoogle Scholar
  • 25 Eschenauer G, DePestel D D, Carver P L. Comparison of echinocandin antifungals.  Therap Clin Risk Management. 2007;  3 71-97
    PubMedGoogle Scholar
  • 26 Dowell J A, Stogniew M, Krause D, Damle B. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment.  J Clin Pharmacol. 2007;  47 461-470
    PubMedGoogle Scholar
  • 27 Hebert M F, Smith H E, Marbury T C et al.. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction.  J Clin Pharmacol. 2005;  45 1145-1152
    CrossrefPubMedGoogle Scholar
  • 28 Goicoechea M, Fierer J, Johns S. Treatment of candidal cholangitis with caspofungin therapy in a patient with a liver transplant: documentation of biliary excretion of caspofungin.  Clin Infect Dis. 2004;  38 1040-1041
    CrossrefPubMedGoogle Scholar
  • 29 Carver P L. Micafungin.  Ann Pharmacother. 2004;  38 1707-1721
    CrossrefPubMedGoogle Scholar
  • 30 Cancidas [package insert]. Rahway, NJ; Merck 2005
    Google Scholar
  • 31 Eraxis [package insert]. New York, NY; Pfizer 2006
    Google Scholar
  • 32 Mycamine [package insert]. Osaka, Japan; Fujisawa 2005
    Google Scholar
  • 33 Okugawa S, Ota Y, Tatsuno K, Tsukada K, Kishino S, Koike K. A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid.  Scand J Infect Dis. 2007;  39 344-346
    CrossrefPubMedGoogle Scholar
  • 34 Sandhu P, Lee W, Xu X et al.. Hepatic uptake of the novel antifungal agent caspofungin.  Drug Metab Dispos. 2005;  33 676-682
    CrossrefPubMedGoogle Scholar
  • 35 Keirns J, Sawamoto T, Holum M, Buell D, Wisemandle W, Alak A. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults.  Antimicrob Agents Chemother. 2007;  51 787-790
    PubMedGoogle Scholar
  • 36 Dowell J A, Schranz J, Baruch A, Foster G. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.  J Clin Pharmacol. 2005;  45 1373-1382
    PubMedGoogle Scholar
  • 37 Dowell J A, Stogniew M, Krause D et al.. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine.  J Clin Pharmacol. 2005;  45 227-233
    PubMedGoogle Scholar
  • 38 Hebert M F, Townsend R W, Austin S et al.. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers.  J Clin Pharmacol. 2005;  45 954-960
    PubMedGoogle Scholar
  • 39 Dowell J A, Stogniew M, Krause D, Henkel T, Damle B. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus.  J Clin Pharmacol. 2007;  47 305-314
    PubMedGoogle Scholar
  • 40 Hebert M F, Blough D K, Townsend R W et al.. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers.  J Clin Pharmacol. 2005;  45 1018-1024
    PubMedGoogle Scholar
  • 41 Bennett J E. Echinocandins for candidemia in adults without neutropenia.  N Engl J Med. 2006;  355 1154-1159
    CrossrefPubMedGoogle Scholar
  • 42 Villanueva A, Gotuzzo E, Arathoon E et al.. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis.  Am J Med. 2002;  113 294-299
    CrossrefPubMedGoogle Scholar
  • 43 de Wet N, Llanos-Cuentas A, Suleiman J et al.. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.  Clin Infect Dis. 2004;  39 842-849
    CrossrefPubMedGoogle Scholar
  • 44 Krause D S, Sinjee A E, van Rensburg C et al.. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.  Clin Infect Dis. 2004;  39 770-775
    CrossrefPubMedGoogle Scholar
  • 45 Mora-Duarte J, Betts R, Rotstein C et al.. Caspofungin vs amphotericin B deoxycholate in the treatment of invasive candidiasis in neutropenic and non-neutropenic patients: a multi-centre, randomized, double-blind study.  N Engl J Med. 2002;  347 2020-2029
    CrossrefPubMedGoogle Scholar
  • 46 Kuse E R, Chetchotisakd P, da Cunha C A et al.. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.  Lancet. 2007;  369 1519-1524
    CrossrefPubMedGoogle Scholar
  • 47 Pappas P G, Rotstein C MF, Betts R F et al.. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.  Clin Infect Dis. 2007;  45 883-893
    CrossrefPubMedGoogle Scholar
  • 48 Reboli A C, Rotstein C, Pappas P G et al.. Anidulafungin versus fluconazole for invasive candidiasis.  N Engl J Med. 2007;  356 2472-2482
    CrossrefPubMedGoogle Scholar
  • 49 Nevado J, De Alarcon A, Hernandez A. Caspofungin: a new therapeutic option for fungal endocarditis.  Clin Microbiol Infect. 2005;  11 248
    CrossrefPubMedGoogle Scholar
  • 50 Rajendram R, Alp N J, Mitchell A R et al.. Candida prosthetic valve endocarditis cured by caspofungin therapy without valvular replacement.  Clin Infect Dis. 2005;  40 e72-e74
    CrossrefPubMedGoogle Scholar
  • 51 Prabhu R M, Orenstein R. Failure of caspofungin to treat brain abscesses secondary to Candida albicans prosthetic valve endocarditis.  Clin Infect Dis. 2004;  39 1253-1254
    CrossrefPubMedGoogle Scholar
  • 52 Gauthier G M, Nork T M, Prince R et al.. Subtherapeutic ocular penetration of caspofunguin and associated treatment failure in Candida albicans endophthalmitis.  Clin Infect Dis. 2005;  41 e27-e28
    CrossrefPubMedGoogle Scholar
  • 53 Sarria J C, Bradley J C, Habash R et al.. Candida glabrata endophthalmitis treated successfully with caspofungin.  Clin Infect Dis. 2005;  40 e46-e48
    CrossrefPubMedGoogle Scholar
  • 54 Liu K H, Wu C J, Chou C H et al.. Refractory candidal meningitis in an immunocompromised patient cured by caspofungin.  J Clin Microbiol. 2004;  42 5950-5953
    CrossrefPubMedGoogle Scholar
  • 55 Maertens J, Raad I, Petrikkos G et al.. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.  Clin Infect Dis. 2004;  39 1563-1571
    CrossrefPubMedGoogle Scholar
  • 56 Candoni A, Mestroni R, Damiani D et al.. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematological malignancies.  Eur J Haematol. 2005;  75 227-233
    CrossrefPubMedGoogle Scholar
  • 57 Denning D W, Marr K A, Lau W M et al.. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.  J Infect. 2006;  53 337-349
    CrossrefPubMedGoogle Scholar
  • 58 Aliff T B, Maslak P G, Jurcic J G et al.. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin B.  Cancer. 2003;  97 1025-1032
    CrossrefPubMedGoogle Scholar
  • 59 Kontoyiannis D P, Hachem R, Lewis R E et al.. Efficacy and toxicity of caspofungin in combination with amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies.  Cancer. 2003;  98 292-299
    CrossrefPubMedGoogle Scholar
  • 60 Marr K A, Boeckh M, Carter R A, Kim H W, Corey L. Combination antifungal therapy for invasive aspergillosis.  Clin Infect Dis. 2004;  39 797-802
    CrossrefPubMedGoogle Scholar
  • 61 Singh N, Limaye A, Forrest G et al.. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study.  Transplantation. 2006;  81 320-326
    CrossrefPubMedGoogle Scholar
  • 62 Walsh T J, Teppler H, Donowitz G R et al.. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.  N Engl J Med. 2004;  351 1391-1402
    CrossrefPubMedGoogle Scholar
  • 63 Van Burik J-AH, Ratanatharathorn V, Stepan D E et al.. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.  Clin Infect Dis. 2004;  39 1407-1416
    CrossrefPubMedGoogle Scholar
  • 64 Krause D S, Reinhardt J, Vazquez J A et al.. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia.  Antimicrob Agents Chemother. 2004;  48 2021-2024
    CrossrefPubMedGoogle Scholar
  • 65 Sable C A, Nguyen B Y, Chodakewitz J A, DiNubile M J. Safety and tolerability of caspofungin acetate in the treatment of fungal infections.  Transpl Infect Dis. 2002;  4 25-30
    CrossrefPubMedGoogle Scholar
  • 66 Heresi G P, Gerstmann D R, Reed M D et al.. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants.  Pediatr Infect Dis J. 2006;  25 1110-1115
    PubMedGoogle Scholar
  • 67 Benjamin Jr D K, Driscoll T, Seibel N L et al.. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.  Antimicrob Agents Chemother. 2006;  50 632-638
    CrossrefPubMedGoogle Scholar
  • 68 Seibel N L, Schwartz C, Arrieta A et al.. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients.  Antimicrob Agents Chemother. 2005;  49 3317-3324
    CrossrefPubMedGoogle Scholar
  • 69 Walsh T J, Adamson P C, Seibel N L et al.. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents.  Antimicrob Agents Chemother. 2005;  49 4536-4545
    CrossrefPubMedGoogle Scholar
  • 70 Marr K A, Hachem R, Papanicolaou G et al.. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporine A.  Transpl Infect Dis. 2004;  3 110-116
    PubMedGoogle Scholar
  • 71 Sanz-Rodriguez C, Lopez-Duarte M, Jurado M et al.. Safety of the concomitant use of caspofungin and cyclosporine A in patients with invasive fungal infections.  Bone Marrow Transplant. 2004;  34 13-20
    CrossrefPubMedGoogle Scholar

Carol A KauffmanM.D. 

Veterans Affairs Ann Arbor Healthcare System

2215 Fuller Rd., Ann Arbor, MI 48105

Email: ckauff@umich.edu